Geneva, 20 April 2015 A new study entitled Understanding the Role and Use of Essential Medicines Lists conducted by the IMS Institute for Healthcare Informatics reveals how Essential Medicines Lists (EML) operate today. The study was commissioned by the IFPMA and aims to give a brief on the role and use of the World Health...
Read moreA new study entitled The Economic Footprint of the Pharmaceutical Industry – Regional breakdown and differentiation between originators and generics, independently conducted by WifOR reveals how the pharmaceutical industry, one of the world’s largest industries, plays a major role in boosting the global economy across regions. The study was commissioned by the IFPMA and aims...
Read moreTo: Chancellor Angela Merkel, Federal Republic of Germany, President of the 2015 G7 Prime Minister Shinzō Abe, Japan Prime Minister David Cameron, United Kingdom Prime Minister Stephen Harper, Canada President François Hollande, Republic of France President Barack Obama, United States of America Prime Minister Matteo Renzi, Republic of Italy Cc: G7 Foreign Ministers and G7...
Read moreReport shows 13% annual increase of pharmaceutical R&D projects to develop treatments to eliminate and control neglected diseases. In 2014, 186 projects were underway. 38 vaccines and treatments currently undergo clinical trials, 10 of which are in final stages. Projects include potential treatments and vaccines for TB, sleeping sickness, malaria, dengue, Chagas, schistosomiasis, intestinal...
Read moreDelivered by Mario Ottiglio, Director, Public Affairs, Communications & Global Health Policy WHO Executive Board 136 – Item 9.4, 2014 Ebola virus disease outbreak Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies and national and regional industry associations across the world. In response to the...
Read moreThe anti-doping and pharmaceutical communities convened in Japan today for the Second International Conference on the Pharmaceutical Industry and the Fight against Doping. The Conference, titled ‘New Developments for Clean Sport and Society, took place at Meiji-Kinen-kan in Tokyo, and followed on from the groundbreaking inaugural event in Paris in November 2012. The event was...
Read moreDelivered by Mario Ottiglio, Director, Public Affairs, Communications & Global Health Policy Check against delivery – Item 8.1, Antimicrobial Resistance Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA highly commends the WHO Secretariat...
Read moreDelivered by Mario Ottiglio, Director, Public Affairs, Communications & Global Health Policy Check against delivery – Item 5.1, Framework of engagement with non-State actors Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA welcomes...
Read moreDelivered by Laetitia Bigger, Senior Manager, Vaccines Policy Check against delivery – Item 9.3, Global Vaccine Action Plan Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA member companies are proud of their role...
Read moreGeneva, 22 January 2015. On the occasion of the 2nd Gavi Replenishment meeting, the International Federation of Pharmaceutical Manufacturers and & Associations (IFPMA) and its member companies stand committed to support the Decade of Vaccines Global Vaccine Action Plan (GVAP) and its key goals. Vaccines are recognized as one of the most cost-effective health interventions,...
Read more04 NOVEMBER 2014, • Stefan Oschmann, Member of the Executive Board and CEO Pharma at Merck, takes over as President of IFPMA from John Lechleiter, Chairman, President and CEO Eli Lilly & Company. • New President to head up work of IFPMA as it engages with international organizations and global health stakeholders to find effective...
Read moreMr Masafumi Nogimori Representative Director, Chairman of the Board, Astellas Pharma Inc., and Vice President of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Global health conference “Investing for Healthier Societies: Innovation, Inclusiveness and Sustainability” that the IFPMA is hosting in partnership with Devex (4 November 2014, New York) (www.ifpmaassembly2014.org). Thank you very much...
Read more